Literature DB >> 18077133

Breast tumor kinase BRK requires kinesin-2 subunit KAP3A in modulation of cell migration.

Kiven E Lukong1, Stéphane Richard.   

Abstract

BReast tumor Kinase (BRK) also known as protein kinase 6 (PTK6) is a nonreceptor tyrosine kinase overexpressed in the majority of human breast tumors. Although some studies have implicated BRK in signalling, cell proliferation and migration, the precise intracellular role of BRK has not been fully elucidated. The RNA-binding protein Sam68, and adaptor proteins paxillin and STAT3 are the only BRK substrates that link BRK to signal transduction. To identify new BRK substrates, we screened high-density protein filter arrays by large-scale in vitro kinase assays using active recombinant BRK. We identified at least 4 BRK targets comprising the alpha-subunit of stimulatory guanine nucleotide binding protein (GNAS), FL139441, beta-tubulin and kinesin associated protein 3A (KAP3A) and validated them as BRK substrates using a secondary assay. Further characterization revealed that KAP3A is an in vivo substrate of BRK and associates with BRK in breast cancer cells. We show that BRK specifically phosphorylated tyrosine residues at the C-terminus of KAP3A and induces delocalization of KAP3A from punctate nuclear localization to a diffuse nucleo-cytoplasmic pattern. Functionally, we demonstrate that KAP3A knockdown results in suppression of BRK-induced migration of breast cancer cells and show that the C-terminal deletion mutant of KAP3A acts as a dominant negative in BRK-induced cell migration. Our findings therefore reveal new substrates of BRK and define KAP3A as a physiological substrate of BRK during cell migration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077133     DOI: 10.1016/j.cellsig.2007.11.003

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  19 in total

Review 1.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

Review 2.  Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.

Authors:  Haroon A Hussain; Amanda J Harvey
Journal:  World J Clin Oncol       Date:  2014-08-10

3.  Detection of Brk expression in non-small cell lung cancer: clinicopathological relevance.

Authors:  Chuifeng Fan; Yang Zhao; Di Liu; Xiupeng Zhang; Enhua Wang
Journal:  Tumour Biol       Date:  2011-05-21

Review 4.  Brk/PTK6 signaling in normal and cancer cell models.

Authors:  Julie H Ostrander; Andrea R Daniel; Carol A Lange
Journal:  Curr Opin Pharmacol       Date:  2010-09-09       Impact factor: 5.547

5.  PTK6 promotes hepatocellular carcinoma cell proliferation and invasion.

Authors:  Xiaohong Chen; Bo Song; Yuanlong Lin; Lijun Cao; Shiyan Feng; Lin Zhang; Fuxiang Wang
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

6.  PTK6 inhibits down-regulation of EGF receptor through phosphorylation of ARAP1.

Authors:  Shin-Ae Kang; Eun-Saem Lee; Hye-Young Yoon; Paul A Randazzo; Seung-Taek Lee
Journal:  J Biol Chem       Date:  2010-06-16       Impact factor: 5.157

Review 7.  Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK.

Authors:  Patrick M Brauer; Angela L Tyner
Journal:  Biochim Biophys Acta       Date:  2010-02-26

Review 8.  Targeting protein tyrosine kinase 6 in cancer.

Authors:  Milica B Gilic; Angela L Tyner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-09-18       Impact factor: 10.680

9.  Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.

Authors:  Nancy E Castro; Carol A Lange
Journal:  Breast Cancer Res       Date:  2010-08-05       Impact factor: 6.466

10.  Sam68 regulates a set of alternatively spliced exons during neurogenesis.

Authors:  Geetanjali Chawla; Chia-Ho Lin; Areum Han; Lily Shiue; Manuel Ares; Douglas L Black
Journal:  Mol Cell Biol       Date:  2008-10-20       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.